Vivacta to Present Poster at the 44th Oak Ridge Conference
News Apr 11, 2012
Vivacta Limited has announced that it will be presenting a poster at the Oak Ridge Conference: Emerging Technologies for 21st Century Clinical Diagnostics, taking place in San Jose, USA, on 19th-20th April 2012.
The Oak Ridge Conference is the American Association for Clinical Chemistry’s annual forum for emerging clinical diagnostic technologies, and brings together thought leaders from industry, academia, and clinical laboratories. The conference focuses exclusively on pre-commercial technologies.
Vivacta's piezofilm technology platform enables the development of next generation near-patient diagnostic products using a novel immunoassay system for the measurement of analytes in whole-blood.
Each diagnostic test requires only a finger prick sample, providing actionable results within 10 minutes or less.
The poster describes refinements in Vivacta's piezofilm technology platform, particularly in relation to the company’s troponin assay although the benefits apply to the system as a whole.
According to the poster, novel conjugation methods for the attachment of antibodies and small molecules to carbon particles increase the binding capacity of the carbon-antibody conjugates 5-fold, giving much improved signal-to-noise.
As a result, Vivacta has achieved a sensitivity of 10 pg / mL (picograms per millilitre) for its troponin I assay using a 30µL sample.
Dr Aileen McGettrick, Team Leader of the troponin programme at Vivacta presenting at the conference said: "The Oak Ridge conference is renowned for attracting leading scientists and technologists to present their latest successes across a range of cutting-edge disciplines including diagnostics. I am delighted that the organizers have accepted our poster for presentation at the meeting."
A new study has identified a drug that potentially could make a common type of immunotherapy for cancer even more effective. The study in laboratory mice found that the drug dasatinib, which is FDA-approved to treat certain types of leukemia, greatly enhances responses to a form of immunotherapy that is used against a wide range of other cancers.